嚴(yán)重過(guò)敏反應(yīng)的加重因素及作用機(jī)制

姜楠楠，尹　佳

[中國(guó)醫(yī)學(xué)科學(xué)院 北京協(xié)和醫(yī)學(xué)院 北京協(xié)和醫(yī)院變態(tài)(過(guò)敏)反應(yīng)科， 北京 100730]

ChinJAllergyClinImmunol，2016，10(3)：269- 275

經(jīng)典的Ⅰ型變態(tài)反應(yīng)的發(fā)生是變應(yīng)原結(jié)合在肥大細(xì)胞表面IgE抗體并使其橋聯(lián)，通過(guò)信號(hào)傳導(dǎo)引起組胺等生物活性物質(zhì)的釋放，從而導(dǎo)致臨床癥狀的發(fā)生。嚴(yán)重過(guò)敏反應(yīng)是最嚴(yán)重的Ⅰ型變態(tài)反應(yīng)，其臨床診斷標(biāo)準(zhǔn)是累及兩個(gè)及兩個(gè)以上的系統(tǒng)，主要包括皮膚、胃腸道系統(tǒng)、呼吸系統(tǒng)、心血管系統(tǒng)等。癥狀輕重不同，可在幾分鐘之內(nèi)從最輕微的皮膚癥狀迅速發(fā)展至死亡[1]。

嚴(yán)重過(guò)敏反應(yīng)的臨床流行病學(xué)數(shù)據(jù)有很大差異，可能是嚴(yán)重過(guò)敏反應(yīng)的臨床診斷標(biāo)準(zhǔn)不一致所致。2006年美國(guó)變態(tài)反應(yīng)、哮喘與免疫學(xué)學(xué)會(huì)(The American Academy of Allergy, Asthma & Immunology，AAAAI)一項(xiàng)系統(tǒng)回顧研究顯示嚴(yán)重過(guò)敏反應(yīng)的終生患病率是0.05%～0.2%[2]，2013年歐洲變應(yīng)性反應(yīng)與臨床免疫學(xué)會(huì)(European Academy of Allergy and Clinical Immunology，EAACI)的一項(xiàng)系統(tǒng)回顧研究顯示歐洲國(guó)家嚴(yán)重過(guò)敏反應(yīng)發(fā)病率是(1.5～7.9)/10萬(wàn)人年[3]。盡管嚴(yán)重過(guò)敏反應(yīng)的發(fā)生大多是由變應(yīng)原誘發(fā)，但伴發(fā)因素在其中的作用越來(lái)越受到重視。運(yùn)動(dòng)是最早被人們認(rèn)識(shí)也是目前研究最多的伴發(fā)因素。食物依賴運(yùn)動(dòng)誘發(fā)的嚴(yán)重過(guò)敏反應(yīng)(food-dependent exercise induced anaphylaxis，F(xiàn)DEIA)已被單獨(dú)列為一種疾病。1979年Maulitz 等[4]首次報(bào)道了貝類依賴運(yùn)動(dòng)誘發(fā)的嚴(yán)重過(guò)敏反應(yīng)。其他研究較多的伴發(fā)因素為非甾體類抗炎藥如阿司匹林、酒精及感染性疾病[1,5- 9]。 歐洲國(guó)家嚴(yán)重過(guò)敏反應(yīng)的研究及登記數(shù)據(jù)顯示[7,10- 14]，30%成人嚴(yán)重過(guò)敏反應(yīng)有伴發(fā)因素存在，3%～23%嚴(yán)重過(guò)敏反應(yīng)發(fā)生在運(yùn)動(dòng)過(guò)程中，1%～15.2%的嚴(yán)重過(guò)敏反應(yīng)有酒精因素參與，6.1%～9%的重度嚴(yán)重過(guò)敏反應(yīng)阿司匹林為伴發(fā)因素，2.5%～3%兒童嚴(yán)重過(guò)敏反應(yīng)有感染性因素的參與，而在成人嚴(yán)重過(guò)敏反應(yīng)中的比例為1.3%～11%。確定變應(yīng)原誘因及伴發(fā)因素是嚴(yán)重過(guò)敏反應(yīng)的診斷、危險(xiǎn)因素評(píng)估以及患者教育的關(guān)鍵，可降低患者發(fā)生致命性嚴(yán)重過(guò)敏反應(yīng)的風(fēng)險(xiǎn)。目前關(guān)于伴發(fā)因素在過(guò)敏休克發(fā)生中的作用機(jī)制主要是增加變應(yīng)原生物利用度和降低效應(yīng)細(xì)胞活化的閾值[15]。

運(yùn)動(dòng)依賴的嚴(yán)重過(guò)敏反應(yīng)及其機(jī)制研究

Maulitz 等[4]首次提出了運(yùn)動(dòng)是嚴(yán)重過(guò)敏反應(yīng)的伴發(fā)/加重因素。他報(bào)道了1例患者在進(jìn)食貝類后慢跑過(guò)程中出現(xiàn)嚴(yán)重過(guò)敏反應(yīng)，但運(yùn)動(dòng)和貝類作為單獨(dú)激發(fā)不能導(dǎo)致嚴(yán)重過(guò)敏反應(yīng)的發(fā)生。隨后報(bào)道了一系列類似病例，F(xiàn)DEIA被定義為一類疾病。盡管運(yùn)動(dòng)依賴的嚴(yán)重過(guò)敏反應(yīng)并不只發(fā)生于食物過(guò)敏的患者，F(xiàn)DEIA是最常見(jiàn)的類型。目前已有研究顯示多種食物可導(dǎo)致FDEIA的發(fā)生，比如開(kāi)心果、肉類、蝦、小麥等[16]。FDEIA常發(fā)生在慢跑過(guò)程中，但癥狀可由輕度和中度運(yùn)動(dòng)強(qiáng)度誘發(fā)[17]。對(duì)敏感患者來(lái)說(shuō)，輕微日?；顒?dòng)足以誘發(fā)嚴(yán)重過(guò)敏反應(yīng)，比如1例肉類過(guò)敏老年女性在熨衣服過(guò)程中發(fā)生嚴(yán)重過(guò)敏反應(yīng)[18]。

目前，小麥依賴運(yùn)動(dòng)誘發(fā)的嚴(yán)重過(guò)敏反應(yīng)(wheat-dependent exercise induced anaphylaxis,WDEIA)為FDEIA最常見(jiàn)的類型。Palosuo 等[19]首次提出了WDEIA。檢測(cè)血清小麥醇溶蛋白ω- 5-gliadin (Tri a 19)特異性IgE的水平是診斷WDEIA最有價(jià)值的工具[20]。運(yùn)動(dòng)作為伴發(fā)因素在食物誘發(fā)嚴(yán)重過(guò)敏反應(yīng)中的作用機(jī)制主要集中于以下兩個(gè)方面：其一是運(yùn)動(dòng)增加了食物變應(yīng)原的生物利用度，另一方面運(yùn)動(dòng)降低肥大細(xì)胞和嗜堿粒細(xì)胞活化閾值。WDEIA的研究顯示，運(yùn)動(dòng)可通過(guò)破壞腸道屏障，增加小腸對(duì)變應(yīng)原的吸收，Matsuo 等[21]研究顯示W(wǎng)DEIA患者進(jìn)食小麥制品后運(yùn)動(dòng)可以顯著增加血清小麥醇溶蛋白的水平，可能的原因是運(yùn)動(dòng)可導(dǎo)致小腸屏障的破壞，但有研究顯示只有高強(qiáng)度和長(zhǎng)時(shí)間(>8 h)的運(yùn)動(dòng)才可引起小腸屏障的破壞，而且誘發(fā)FDEIA的運(yùn)動(dòng)強(qiáng)度有很大差異，即使是輕微活動(dòng)也可誘發(fā)癥狀，所以除了運(yùn)動(dòng)引起小腸屏障破壞機(jī)制外，可能還另有機(jī)制介導(dǎo)[22]。Yano等[23]的研究顯示蛋白溶菌酶致敏的小鼠給予口服溶菌酶激發(fā)后，運(yùn)動(dòng)組和非運(yùn)動(dòng)組小鼠小腸攝取溶菌酶均有增加，說(shuō)明致敏本身即可導(dǎo)致小腸屏障的破壞。腸道對(duì)變應(yīng)原的吸收增加可能受個(gè)體致敏程度和運(yùn)動(dòng)強(qiáng)度的雙重影響。

除了增加變應(yīng)原的生物利用度，運(yùn)動(dòng)還可影響肥大細(xì)胞和嗜堿粒細(xì)胞活化閾值。對(duì)于肥大細(xì)胞來(lái)說(shuō)，這種假設(shè)主要基于運(yùn)動(dòng)后速發(fā)型皮膚反應(yīng)的改變。FDEIA患者運(yùn)動(dòng)后皮膚對(duì)特定變應(yīng)原的反應(yīng)性增強(qiáng)[24]。有學(xué)者提出高強(qiáng)度的運(yùn)動(dòng)可通過(guò)血漿滲透壓增加和pH值的改變影響效應(yīng)細(xì)胞的閾值[22,25- 26]，他們通過(guò)體外研究顯示滲透壓達(dá)到340 mOsm才可使肥大細(xì)胞活化閾值下降，即使在高強(qiáng)度運(yùn)動(dòng)如跑半程馬拉松后，滲透壓僅能升高至293 mOsm[22]，所以通過(guò)血漿滲透壓改變效應(yīng)細(xì)胞活性的理論有待進(jìn)一步研究。另一個(gè)可能的原因是腸道黏膜谷氨酰胺轉(zhuǎn)胺酶活化使效應(yīng)細(xì)胞脫顆粒增加，有研究顯示長(zhǎng)跑后白細(xì)胞介素- 6(interleukin- 6，IL- 6)的表達(dá)量增加50～100倍[27]，IL- 6誘導(dǎo)腸道黏膜谷氨酰胺轉(zhuǎn)胺酶活化從而導(dǎo)致ω- 5-醇溶蛋白肽段的聚合，使效應(yīng)細(xì)胞上的sIgE橋聯(lián)活化效應(yīng)細(xì)胞[28]。此外運(yùn)動(dòng)誘發(fā)的內(nèi)啡肽釋放能夠使肥大細(xì)胞或者嗜堿粒細(xì)胞活化，一項(xiàng)體外研究顯示β內(nèi)啡肽可導(dǎo)致肥大細(xì)胞脫顆粒和組胺釋放。過(guò)敏性鼻炎患者的鼻腔給予β內(nèi)啡肽和變應(yīng)原激發(fā)后鼻腔分泌物中的組胺水平顯著增高[29]，而只給予內(nèi)啡肽的患者組胺水平?jīng)]有變化[30]。

盡管目前相關(guān)科研數(shù)據(jù)有限，但仍可得出以下結(jié)論：(1)運(yùn)動(dòng)可增加腸道對(duì)變應(yīng)原的吸收；(2)誘發(fā)嚴(yán)重過(guò)敏反應(yīng)的運(yùn)動(dòng)強(qiáng)度取決于多種因素，如患者致敏狀態(tài)。在某些患者，伴發(fā)因素可同時(shí)存在，如運(yùn)動(dòng)+酒精或者運(yùn)動(dòng)+阿司匹林。

藥物依賴的嚴(yán)重過(guò)敏反應(yīng)及機(jī)制研究

非甾體類抗炎藥

一些藥物可以參與食物誘發(fā)的嚴(yán)重過(guò)敏反應(yīng)，非甾體類抗炎藥是研究最多的藥物伴發(fā)因素。1984年Cant等[31]首次報(bào)道了1例14歲男孩服用阿司匹林后進(jìn)食花生誘發(fā)嚴(yán)重過(guò)敏反應(yīng)，既往單獨(dú)進(jìn)食花生僅有一過(guò)性輕度過(guò)敏反應(yīng)發(fā)生。Flemstrom 等[32]在右旋糖酐過(guò)敏的豚鼠模型中，單純給予右旋糖酐無(wú)反應(yīng)，而同時(shí)給予右旋糖酐和阿司匹林可誘發(fā)休克。與運(yùn)動(dòng)效應(yīng)類似，阿司匹林可能增加變應(yīng)原的腸道吸收。Matsuo等[21]研究顯示，WDEIA患者同時(shí)攝入小麥制品和阿司匹林比單純攝入小麥的患者血清醇溶蛋白的濃度高5倍。另一可能的機(jī)制是，阿司匹林影響小腸屏障緊密連接的建立。體外模型實(shí)驗(yàn)顯示給予豚鼠5 mmol/L的阿司匹林可以減少緊密連接蛋白- 7的產(chǎn)生，從而顯著增加右旋糖酐的通透性[32]。

除了增加變應(yīng)原的腸道吸收外，非甾體類抗炎藥或可直接調(diào)節(jié)效應(yīng)細(xì)胞活性。體外研究顯示肥大細(xì)胞提前用阿司匹林孵育能直接介導(dǎo)FcεRⅠ依賴的肥大細(xì)胞脫顆粒和白三烯C4(Leukotriene C4，LTC4)釋放[33- 34]。FDEIA患者[21,35]提前服用阿司匹林能增加食物變應(yīng)原的皮膚反應(yīng)性。

其他藥物

能導(dǎo)致肥大細(xì)胞和嗜堿粒細(xì)胞介質(zhì)釋放的藥物均為潛在的IgE介導(dǎo)的嚴(yán)重過(guò)敏反應(yīng)的伴發(fā)因素，如碘造影劑、抗生素及某些阿片類藥物[36- 37]。由于胃酸消化可降低食物變應(yīng)原的變應(yīng)原性，一些抑制胃酸分泌的藥物如H2受體拮抗劑、質(zhì)子泵抑制劑等可使胃酸的pH值升高，從而不能有效降低食物變應(yīng)原的變應(yīng)原性，導(dǎo)致大分子變應(yīng)原到達(dá)腸道誘發(fā)局部或系統(tǒng)性變態(tài)反應(yīng)的發(fā)生。Diesner等[38]對(duì)卵清蛋白致敏的小鼠應(yīng)用質(zhì)子泵抑制劑可增加激發(fā)試驗(yàn)中嚴(yán)重過(guò)敏反應(yīng)發(fā)生風(fēng)險(xiǎn)。Untersmayr等[39]一項(xiàng)前瞻性研究顯示10%患者服用質(zhì)子泵抑制劑治療3個(gè)月后血清原有食物特異性IgE水平顯著增高，而15%患者出現(xiàn)新的食物特異性IgE抗體。若特應(yīng)性個(gè)體對(duì)某種胃酸不耐受的食物變應(yīng)原過(guò)敏，臨床僅表現(xiàn)為口腔變態(tài)反應(yīng)綜合征，在服用質(zhì)子泵抑制劑期間大量食入該變應(yīng)原，有發(fā)生嚴(yán)重過(guò)敏反應(yīng)的風(fēng)險(xiǎn)[39- 40]。

有研究顯示抗高血壓藥物能增加重度嚴(yán)重過(guò)敏反應(yīng)發(fā)生風(fēng)險(xiǎn)。Lee等[41]對(duì)302例急診嚴(yán)重過(guò)敏反應(yīng)的患者研究顯示服用抗高血壓藥物的個(gè)體重度嚴(yán)重過(guò)敏反應(yīng)的風(fēng)險(xiǎn)增加1.8倍，住院風(fēng)險(xiǎn)增加3倍。Rueff等[8]的研究顯示重度蜂毒嚴(yán)重過(guò)敏反應(yīng)與血管緊張素轉(zhuǎn)化酶抑制劑類藥物應(yīng)用相關(guān)，而與腎上腺素β受體拮抗劑的應(yīng)用不相關(guān)。然而，Brown等[42]的研究顯示，腎上腺素β受體拮抗劑和血管緊張素轉(zhuǎn)化酶抑制劑類藥物應(yīng)用不增加重度嚴(yán)重過(guò)敏反應(yīng)發(fā)作風(fēng)險(xiǎn)，這說(shuō)明抗高血壓藥物與嚴(yán)重過(guò)敏反應(yīng)的相關(guān)性還不明確，可能的機(jī)制為腎上腺素β受體拮抗劑(普萘洛爾、美托洛爾等)通過(guò)β腎上腺素受體cAMP系統(tǒng)效應(yīng)細(xì)胞(肥大細(xì)胞、嗜堿粒細(xì)胞)使信號(hào)傳導(dǎo)通路受到抑制，導(dǎo)致效應(yīng)細(xì)胞不穩(wěn)定[43]。另外，腎上腺素β受體拮抗劑加重嚴(yán)重過(guò)敏反應(yīng)的機(jī)制可能與心臟收縮力下降，干擾了腎上腺素的治療作用有關(guān)[41]。血管緊張素轉(zhuǎn)化酶可以使緩激肽失活，血管緊張素轉(zhuǎn)化酶抑制劑類藥物的應(yīng)用可使緩激肽水平升高[44]。緩激肽能促進(jìn)一氧化氮的合成，使血管擴(kuò)張。緩激肽和其他炎性介質(zhì)的累積可誘發(fā)血管痙攣[45]。此外，緩激肽水平的急速升高可導(dǎo)致嚴(yán)重的咽喉部水腫[46]。因此，血管緊張素轉(zhuǎn)化酶抑制劑類的藥物可導(dǎo)致血管神經(jīng)性水腫、低血壓以及氣管痙攣。Summers等[47]研究花生堅(jiān)果過(guò)敏的患者，血清血管緊張素轉(zhuǎn)化酶水平降低與喉頭水腫相關(guān)，而與氣管痙攣、意識(shí)喪失不相關(guān)。血清血管緊張素轉(zhuǎn)化酶水平<37.0 mmol/L的患者發(fā)生嚴(yán)重喉頭水腫的風(fēng)險(xiǎn)增加8.6倍。Lee等[41]的研究未顯示這種相關(guān)性，而在該項(xiàng)研究中應(yīng)用血管緊張素轉(zhuǎn)化酶抑制劑類藥物嚴(yán)重過(guò)敏反應(yīng)的患者3個(gè)以上系統(tǒng)累及的風(fēng)險(xiǎn)增加1.3倍，住院治療的風(fēng)險(xiǎn)增加2.2倍。然而，這些機(jī)制仍然有爭(zhēng)議并有待進(jìn)一步研究。

越來(lái)越多的證據(jù)提示多種藥物可作為嚴(yán)重過(guò)敏反應(yīng)的伴發(fā)因素，尤其是非甾體類抗炎藥類的藥物。因此嚴(yán)重過(guò)敏反應(yīng)的診斷應(yīng)該考慮藥物相關(guān)因素，并告知患者其為嚴(yán)重過(guò)敏反應(yīng)尤其是重度嚴(yán)重過(guò)敏反應(yīng)發(fā)生的危險(xiǎn)因素。肌松劑或造影劑可能誘發(fā)嚴(yán)重過(guò)敏反應(yīng)，醫(yī)師應(yīng)該避免開(kāi)處方或者事先給予糖皮質(zhì)激素或者抗組胺藥預(yù)防。如果有口腔變態(tài)反應(yīng)綜合征的患者需要使用質(zhì)子泵抑制劑類藥物，醫(yī)師應(yīng)告知患者質(zhì)子泵抑制劑類藥物可導(dǎo)致變應(yīng)原不被胃酸完全降解，有誘發(fā)嚴(yán)重過(guò)敏反應(yīng)的風(fēng)險(xiǎn)。心肌梗死、心律失?；蛘邍?yán)重心力衰竭的患者使用腎上腺素β受體拮抗劑，避免應(yīng)用造成的風(fēng)險(xiǎn)會(huì)高于嚴(yán)重過(guò)敏反應(yīng)發(fā)生的風(fēng)險(xiǎn)，是否應(yīng)用腎上腺素β受體拮抗劑取決于個(gè)體的利益風(fēng)險(xiǎn)比。

酒精在嚴(yán)重過(guò)敏反應(yīng)發(fā)生中的作用

Gonzalez-Quintela等[48]的一項(xiàng)成人過(guò)敏性疾病流行病學(xué)顯示，酒精攝入與總IgE水平升高和氣傳花粉致敏相關(guān)。10%食物過(guò)敏[49]或運(yùn)動(dòng)誘發(fā)的嚴(yán)重過(guò)敏反應(yīng)[50]的患者在飲酒后癥狀更容易發(fā)生。Uguz等[14]的研究顯示15.2%成人嚴(yán)重過(guò)敏反應(yīng)中有酒精因素的參與，而法國(guó)食物過(guò)敏在線登記數(shù)據(jù)顯示8.9%的嚴(yán)重過(guò)敏反應(yīng)有酒精因素的參與。與阿司匹林的作用類似，酒精使小腸上皮緊密連接松弛，從而使小腸對(duì)變應(yīng)原尤其是小分子蛋白吸收率增加[22, 51]。但相關(guān)實(shí)驗(yàn)數(shù)據(jù)少見(jiàn)。

感染在嚴(yán)重過(guò)敏反應(yīng)發(fā)生中的作用

多項(xiàng)研究顯示在感染性疾病的早期階段或者輕度感染能夠加重嚴(yán)重過(guò)敏反應(yīng)的發(fā)生[7,9- 14,52]。2.5%～3%兒童嚴(yán)重過(guò)敏反應(yīng)有感染性因素存在，而1.3%～11%成人嚴(yán)重過(guò)敏反應(yīng)有感染因素的存在。感染因素通常與花粉或蜂毒特異性免疫治療(allergen specific immunology，SIT)后出現(xiàn)嚴(yán)重過(guò)敏性反應(yīng)相關(guān)[1, 52]。由于感染因素在SIT后有出現(xiàn)嚴(yán)重過(guò)敏反應(yīng)的風(fēng)險(xiǎn)，SIT的指南已建議在感染情況下暫停SIT的治療。Staden等[53]報(bào)道在25例雞蛋和牛奶口服脫敏的兒童中，12例發(fā)生了嚴(yán)重過(guò)敏反應(yīng)，最常見(jiàn)伴發(fā)因素為運(yùn)動(dòng)和感染。

感染作為嚴(yán)重過(guò)敏反應(yīng)的伴發(fā)因素機(jī)制還不明確。病原體本身可作為變應(yīng)原致敏機(jī)體和產(chǎn)生IgE或使已存在的IgE分子產(chǎn)生橋聯(lián)[54- 56]。另外，IgE、IgM及IgG抗體與抗原能夠形成可溶性的抗原抗體復(fù)合物。在病理情況下，免疫復(fù)合物可通過(guò)補(bǔ)體激活系統(tǒng)導(dǎo)致過(guò)敏毒素C3a和C5a以及促炎因子和趨化因子的產(chǎn)生[57]。除了FcεRⅠ，嗜堿粒細(xì)胞和肥大細(xì)胞也表達(dá)FcγR，其能夠促進(jìn)效應(yīng)細(xì)胞脫顆粒[58]。FcγRⅠ導(dǎo)致的肥大細(xì)胞脫顆粒是由于IgG1亞群介導(dǎo)的[59- 60]。因此，感染過(guò)程中IgG的產(chǎn)生或可影響嚴(yán)重過(guò)敏反應(yīng)的發(fā)生。固有免疫系統(tǒng)可能也可參與Ⅰ型變態(tài)反應(yīng)的發(fā)生。細(xì)菌、真菌以及病毒是通常所說(shuō)的病原體相關(guān)分子模式，能直接連接在病原體識(shí)別受體上從而導(dǎo)致細(xì)胞活化和免疫應(yīng)答而無(wú)需提前致敏[61- 62]。肥大細(xì)胞和嗜堿粒細(xì)胞表達(dá)病原體識(shí)別受體能被不同的病原體相關(guān)分子模式激活[63- 64]，因此能夠調(diào)節(jié)效應(yīng)細(xì)胞的反應(yīng)狀態(tài)[65]。病原體相關(guān)分子模式的肽聚糖能夠誘發(fā)人[66]和大鼠肥大細(xì)胞[67]的脫顆粒。有些病原體相關(guān)分子模式也能調(diào)節(jié)和抑制肥大細(xì)胞的脫顆粒使固有的肥大細(xì)胞的激活處于平衡狀態(tài)[68]。病原體也能夠激活不同系統(tǒng)導(dǎo)致過(guò)敏毒素C3a和C5a的產(chǎn)生。有研究顯示C3a和C5a能觸發(fā)肥大細(xì)胞組胺釋放，C5a的作用強(qiáng)于C3a[69]。然而，C3a和C5a的激活作用僅限于一部分肥大細(xì)胞亞群，因?yàn)轲つし蚀蠹?xì)胞不表達(dá)過(guò)敏毒素的受體[70]，而且其作用于嚴(yán)重過(guò)敏反應(yīng)的機(jī)制還不明確[71]。但細(xì)菌或者病毒產(chǎn)物能夠被肥大細(xì)胞和嗜堿粒細(xì)胞的受體感知，在某些特定的情況下，觸發(fā)或者增強(qiáng)肥大細(xì)胞脫顆粒。但微生物因素作為嚴(yán)重過(guò)敏反應(yīng)的伴發(fā)因素的證據(jù)尚不足，應(yīng)進(jìn)一步研究。了解感染因素是嚴(yán)重過(guò)敏反應(yīng)相關(guān)危險(xiǎn)因素對(duì)SIT治療和管理非常重要，在感染情況下SIT必須暫停或者減少劑量。

小　　結(jié)

嚴(yán)重過(guò)敏反應(yīng)的發(fā)生及其嚴(yán)重程度取決于多種因素，包括變應(yīng)原本身的性質(zhì)、變應(yīng)原的劑量、患者本身的致敏狀態(tài)及變應(yīng)原IgE的結(jié)合力。近年來(lái)，嚴(yán)重過(guò)敏反應(yīng)的伴發(fā)因素在其發(fā)生中的作用受到重視，伴發(fā)因素包括運(yùn)動(dòng)、酒精攝入、藥物以及感染性疾病，其作用機(jī)制仍需要更深入的研究。

[1]Simons FE, Ardusso LR, Bilò MB, et al. World Allergy Organization anaphylaxis guidelines: Summary[J]. J Allergy Clin Immunol, 2011, 127: 587- 593.

[2]Lieberman P, Camargo CA, Bohlke K, et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology epidemiology of Anaphylaxis Working Group [J]. Ann Allergy Asthma Immunol, 2006, 97: 596- 602.

[3]Panesar SS, Javad S, De Silva D, et al. The epidemiology of anaphylaxis in Europe: a systematic review [J]. Allergy, 2013, 68:1353- 1561.

[4]Maulitz RM, Pratt DS, Schocket AL. Exercise-induced anaphylactiv reaction to shellfish [J]. J Allergy Clin Immunol, 1979, 63: 433- 434.

[5]Woelbing F, Biedermann T. Augmentation to Anaphylaxis: The Role of Aspirin and Physical Exercise as Co-factors [J]. Acta Dermato-Venereologica, 2012, 92: 451- 453.

[6]Pfeffer I, Fischer J, Biedermann T. Acetylsalicylic acid dependent anaphylaxis to carrots in a patient with mastocytosis [J]. J Dtsch Dermatol Ges, 2011, 9: 230- 231.

[7]Worm M, Scherer K, Koehli-Wieaner A, et al. Food-induced anaphylaxis and cofactors-data from the anaphylaxis registry [J]. Allergologie, 2011, 34: 329- 337.

[8]Rueff F, Przybilla B, Bilo MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: Importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity [J]. J Allergy Clin Immunol, 2009, 124: 1047- 1054.

[9]Mazur N, Patterson R, Perlman D. A case of idiopathic anaphylaxis associated with respiratory infections [J]. Ann Allergy Asthma Immunol, 1997, 79: 546- 548.

[10] Hompes S, Koehli A, Nemat K, et al. Provoking allergens and treatment of anaphylaxis in children and adolescents-data from the anaphylaxis registry of German-speaking countries [J]. Pediatr Allergy Immunol, 2011, 22: 568- 574.

[11] Mullins RJ. Anaphylaxis: risk factors for recurrence [J]. Clin Exp Allergy, 2003, 33: 1033- 1040.

[12] De Swert LFA, Bullens D, Raes M, et al. Anaphylaxis in referred pediatric patients: demographic and clinical features, triggers, and therapeutic approach [J]. Eur J Pediatr, 2008, 167: 1251- 1261.

[13] Treudler R, Kozovska Y, Simon JC. Severe immediate type hypersensitivity reactions in 105 German adults: When to diagnose anaphylaxis [J]. J Investig Allergol Clin Immunol, 2008, 18: 52- 58.

[14] Uguz A, Lack G, Pumphrey R, et al. Allergic reactions in the community: a questionnaire survey of members of the anaphylaxis campaign [J]. Clin Exp Allergy, 2005, 35: 746- 750.

[15] Wolbing F, Fischer J, Koberle M, et al. About the role and underlying mechanisms of cofactors in anaphylaxis [J]. Allergy, 2013, 68: 1085- 1092.

[16] Wong GK, Krishna MT. Food-Dependent Exercise-Induced Anaphylaxis: Is Wheat Unique? [J]. Curr Allergy Asthma Rep, 2013, 13: 639- 644.

[17] Barg W, Medrala W, Wolanczyk-Medrala A. Exercise-Induced Anaphylaxis: An Update on Diagnosis and Treatment [J]. Curr Allergy Asthma Rep, 2011, 11: 45- 51.

[18] Biedermann T, Schopf P, Rueff F, et al. Exercise-induced anaphylaxis after eating pork or beef [J]. Dtsch Med Wochenschr, 1999, 124: 456- 458.

[19] Palosuo K, Alenius H, Varjonen E, et al. A novel wheat gliadin as a cause of exercise-induced anaphylaxis [J]. J Allergy Clin Immunol, 1999, 103: 912- 917.

[20] Matsuo H, Kohno K, Niihara H, et al. Specific IgE determination to epitope peptides of omega- 5 gliadin and high molecular weight glutenin subunit is a useful tool for diagnosis of wheat-dependent exercise-induced anaphy-laxis [J]. J Immunol, 2005, 175: 8116- 8122.

[21] Matsuo H, Morimoto K, Akaki T, et al. Exercise and aspirin increase levels of circulating gliadin peptides in patients with wheat-dependent exercise-induced anaphylaxis [J]. Clin Exp Allergy, 2005, 35: 461- 466.

[22] Robson-Ansley P, Du Toit G. Pathophysiology, dia-gnosis and management of exercise-induced anaphylaxis [J]. Curr Opin Allergy Clin Immunol, 2010, 10: 312- 317.

[23] Yano H, Kato Y, Matsuda T. Acute exercise induces gastrointestinal leakage of allergen in lysozyme-sensitized mice [J]. Eur J Appl Physiol, 2002, 87: 358- 364.

[24] Romano A, Difonso M, Giuffreda F, et al. Diagnostic work-up for food dependent exercise-induced ana-phylaxis [J]. Allergy, 1995, 50: 817- 824.

[25] Barg W, Wolanczyk-Medrala A, Obojski A, et al. Food-dependent exercise-induced anaphylaxis: Possible impact of increased basophil histamine releasability in hyperosmolar conditions [J]. J Investig Allergol Clin Immunol, 2008, 18: 312- 315.

[26] Wolanczyk-Medrala A, Barg W, Gogolewski G, et al.Influence of hyperosmotic conditions on basophil CD203C upregulation in patients with food-dependent exercise induced anaphylaxis[J]. Ann Agric Environ Med, 2009, 16: 301- 304.

[27] Ostrowski K, Rohde T, Zacho M, et al. Evidence that interleukin- 6 is produced in human skeletal muscle during prolonged running [J]. J Physiol, 1998, 508: 949- 953.

[28] Palosuo K, Varjonen E, Nurkkala J, et al. Transglu-taminase-mediated cross-linking of a peptic fraction of omega- 5 gliadin enhances IgE reactivity in wheat-dependent, exercise-induced anaphylaxis [J]. J Allergy Clin Immunol, 2003, 111: 1386- 1392.

[29] Teofoli P, Frezzolini A, Puddu P, et al. The role of proopiomelanocortin-derived peptides in skin fibroblast and mast cell functions [M]∥Luger TA, Paus R, Lipton JM, et al. Cutaneous Neuroimmunomodul-ation: The Proopiomelanocortin System, 1999: 268- 276.

[30] Baumgarten CR, Schmitz P, O’Connor A, et al. Effects of beta-endorphin on nasal allergic inflammation [J]. Clin Exp Allergy, 2002, 32: 228- 236.

[31] Cant AJ, Gibson P, Dancy M. Food hypersensitivity made life threatening by ingestion of aspirin [J]. British Medical Journal, 1984, 288: 755- 756.

[32] Flemstrom G, Marsden NV, Richter W. Passive cutaneous anaphylaxis in guinea pigs elicited by gastric absorption of dextran induced by acetylsalicylic acid. [J]. Int Arch Allergy Appl Immunol, 1976, 51: 627- 636.

[33] Mortaz E, Redegeld FA, Nijkamp FP, et al. Dual effects of acetylsalicylic acid on mast cell degranulation, expression of cyclooxygenase- 2 and release of pro-inflammatory cytokines [J]. Biochem Pharmacol, 2005, 69: 1049- 1057.

[34] Suzuki Y, Ra C. Analysis of the Mechanism for the Development of Allergic Skin Inflammation and the Application for Its Treatment: Aspirin Modulation of IgE-Dependent Mast Cell Activation: Role of Aspirin-Induced Exacerbation of Immediate Allergy [J]. J Pharmacol Sci, 2009, 110: 237- 244.

[35] Aihara M, Miyazawa M, Osuna H, et al. Food-dependent exercise-induced anaphylaxis: influence of concurrent aspirin administration on skin testing and provocation [J]. Br J Dermatol, 2002, 146: 466- 472.

[36] Brockow K, Ring J. Anaphylaxis to radiographic contrast media [J]. Curr Opin Allergy Clin Immunol, 2011, 11: 326- 331.

[37] Thong BY, Yeow C. Anaphylaxis during surgical and interventional procedures [J]. Ann Allergy Asthma Immunol, 2004, 92: 619- 628.

[38] Diesner SC, Knittelfelder R, Krishnamurthy D, et al. Dose-dependent food allergy induction against ovalbumin under acid-suppression: A murine food allergy model [J]. Immunol Lett, 2008, 121: 45- 51.

[39] Untersmayr E, Jensen-Jarolim E. The effect of gastric digestion on food allergy [J]. Curr Opin Allergy Clin Immunol, 2006, 6: 214- 219.

[40] Untersmayr E, Jensen-Jarolim E. The role of protein digestibility and antacids on food allergy outcomes [J]. J Allergy Clin Immunol, 2008, 121: 1301- 1308.

[41] Lee S, Hess EP, Nestler DM, et al. Antihypertensive medication use is associated with increased organ system involvement and hospitalization in emergency department patients with anaphylaxis [J]. J Allergy Clin Immunol, 2013, 131: 1103- 1108.

[42] Brown SG. Clinical features and severity grading of anaphylaxis [J]. J Allergy Clin Immunol, 2004, 114: 371- 376.

[43] Toogood JH. Risk of anaphylaxis in patients receiving beta-blocker drugs[J]. J Allergy Clin Immunol, 1988, 81: 1- 5.

[44] Blais C, Marceau F, Rouleau JL, et al. The kallikrein-kininogen-kinin system: lessons from the quantification of endogenous kinins [J]. Peptides, 2000, 21: 1903- 1940.

[45] Overlack A. ACE inhibitor-induced cough and bronchos-pasm-Incidence, mechanisms and management [J]. Drug Safety, 1996, 15: 72- 78.

[46] Nussberger J, Cugno M, Amstutz C, et al. Plasma bradykinin in angio-oedema [J]. Lancet, 1998, 351: 1693- 1697.

[47] Summers CW, Pumphrey RS, Woods CN, et al. Factors predicting anaphylaxis to peanuts and tree nuts in patients referred to a specialist center [J]. J Allergy Clin Immunol, 2008, 121: 632- 638.

[48] Gonzalez-Quintela A, Gude F, Boquete O, et al. Association of alcohol consumption with total serum immunoglobulin E levels and allergic sensitization in an adult population-based survey [J]. Clin Exp Allergy, 2003, 33: 199- 205.

[49] Kanny G, Moneret-Vautrin DA, Flabbee J, et al. Population study of food allergy in France [J]. J Allergy Clin Immunol, 2001, 108: 133- 140.

[50] Shadick NA, Liang MH, Partridge AJ, et al. The natural history of exercise-induced anaphylaxis: Survey results from a 10-year follow-up study [J]. J Allergy Clin Immunol, 1999, 104: 123- 127.

[51] Pastorello EA, Farioli L, Pravettoni V, et al. Iden-tification of grape and wine allergens as an endochitinase 4, a lipid-transfer protein, and a thaumatin [J]. J Allergy Clin Immunol, 2003, 111: 350- 359.

[52] Bousquet J, Menardo JL, Velasquez G, et al. Systemic reactions during maintenance immunotherapy with honey bee venom[J].Ann Allergy, 1988, 61: 63- 68.

[53] Staden U, Rolinck-Werninghaus C, Brewe F, et al. Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction [J]. Allergy, 2007, 62: 1261- 1269.

[54] Grunewald SM, Hahn C, Wohlleben G, et al. Infection with influenza A virus leads to flu antigen-induced cutaneous anaphylaxis in mice [J]. J Invest Dermatol, 2002, 118: 645- 651.

[55] Sharma BK, Talwar KK, Bhatnagar V, et al. Recurrent anaphylaxis due to plasmodium vivax infeciton [J]. Lancet, 1979, 1: 1340- 1341.

[56] Vuitton DA. Echinocloccosis and allergy [J]. Clin Rev Allergy Immunol, 2004, 26: 93- 104.

[57] Simons FE. Anaphylaxis: Recent advances in assess-ment and treatment [J]. J Allergy Clin Immunol, 2009, 124: 625- 636.

[58] Tkaczyk C, Okayama Y, Metcalfe DD, et al. Fc gamma receptors on mast cells: Activatory and inhibitory regulation of mediator release [J]. Int Arch Allergy Immunol, 2004, 133: 305- 315.

[59] Okayama Y, Hagaman DD, Metcalfe DD. A comparison of mediators released or generated by IFN-gamma-treated human mast cells following aggregation of Fc gamma RI or Fc epsilon RI [J]. J Immunol, 2001, 166: 4705- 4712.

[60] Okayama Y, Tkaczyk C, Metcalfe DD, et al. Comparison of Fc epsilon RI-and Fc gamma RI-mediated degranulation and TNF-alpha synthesis in human mast cells: selective utilization of phosphatidylinositol-3-kinase for Fc gamma Ri-induced degranulation [J]. European J Immunol, 2003, 33: 1450- 1459.

[61] Volz T, Kaesler S, Biedermann T. Innate immune sensing 2.0-from linear activation pathways to fine tuned and regulated innate immune networks [J]. Exp Dermatol, 2012, 21: 61- 69.

[62] Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system [J]. Int Rev Immunol, 2011, 30: 16- 34.

[63] Fukata M, Vamadevan AS, Abreu MT. Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders [J]. Seminars in Immunology, 2009, 21: 242- 253.

[64] Metz M, Maurer M. Mast cells-key effector cells in immune responses [J]. Trends Immunol, 2007, 28: 234- 241.

[65] Qiao HH, Andrade MV, Lisboa FA, et al. Fc epsilon R1 and toll-like receptors mediate synergistic signals to markedly augment production of inflammatory cytokines in murine mast cells [J]. Blood, 2006, 107: 610- 618.

[66] Wu L, Feng BS, He SH, et al. Bacterial peptidoglycan breaks down intestinal tolerance via mast cell activation: The role of TLR2 and NOD2 [J]. Immunol Cell Biol, 2007, 85: 538- 545.

[67] Supajatura V, Ushio H, Nakao A, et al. Differential responses of mast cell Toll-like receptors 2 and 4 in allergy and innate immunity [J]. J Clin Invest, 2002, 109: 1351- 1359.

[68] Kasakura K, Takahashi K, Aizawa T, et al. A TLR2 ligand suppresses allergic inflammatory reactions by acting directly on mast cells [J]. Int Arch Allergy Immunol, 2009, 150: 359- 369.

[69] Erdei A, Kerekes K, Pecht I. Role of C3a and C5a in the activation of mast cells [J]. Exp Clin Immunogenet, 1997, 14: 16- 18.

[70] Ali H. Regulation of human mast cell and basophil function by anaphylatoxins C3a and C5a [J]. Immunol Lett, 2010, 128: 36- 45.

[71] Windbichler M, Echtenacher B, Takahashi K, et al. Investigations on the involvement of the lectin pathway of complement activation in anaphylaxis [J]. Int Arch Allergy Immunol, 2006, 141: 11- 23.